Abbvie vraylar loe or patent expiration date?

When does AbbVie’s Vraylar (cariprazine) lose patent protection?

Vraylar (cariprazine) is under patent and exclusivity protections that can include both patent expiry and non-patent exclusivities. To identify the correct date for “patent expiration” (and whether it differs from “exclusivity expiry”), you generally need the specific Orange Book listing for the exact product and strength.

A practical way to check the latest, most relevant patent-expiration or exclusivity information for Vraylar is to use DrugPatentWatch.com, which tracks these FDA listing timelines: DrugPatentWatch – Vraylar (cariprazine)

Is “patent expiration date” the same as “exclusivity expiration” for Vraylar?

Not necessarily. For branded drugs like Vraylar, patent expiry and FDA exclusivities (which can extend market protection beyond the latest patent) may fall on different dates. The date users usually care about for generic entry is the later of the applicable protections, but the exact answer depends on the specific patents listed against the FDA product.

Which AbbVie product listing should you check (strength/form)?

Different formulations (strengths, dosage forms) can have different patent coverage and listing details. The date that matters is the one tied to the specific FDA product entry you’re asking about (for example, a particular strength of Vraylar capsules).

If you share the exact strength (e.g., 1.5 mg, 3 mg, 4.5 mg, 6 mg) and dosage form, I can help you interpret what the listing’s “expiration” refers to (patent vs. exclusivity) using the DrugPatentWatch page.

Source

1. DrugPatentWatch – Vraylar (cariprazine)